Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits

Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits

Abstract Mpro, the main protease of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is essential for the viral life cycle. Accordingly, several groups have performed in silico screens to identify Mpro inhibitors that might be used to treat SARS-CoV-2 infections. We selected more th...

Full description

Bibliographic Details
Main Authors: Giacomo G. Rossetti, Marianna A. Ossorio, Stephan Rempel, Annika Kratzel, Vasilis S. Dionellis, Samia Barriot, Laurence Tropia, Christoph Gorgulla, Haribabu Arthanari, Volker Thiel, Peter Mohr, Remo Gamboni, Thanos D. Halazonetis
Format: Article
Language:English
Published: Nature Portfolio 2022-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-06306-4

Internet

https://doi.org/10.1038/s41598-022-06306-4

Similar Items